President Donald Trump has introduced a new website, TrumpRx.gov, offering over 40 medicines at much lower prices for people paying with cash. This website started on February 5th and includes drugs from five major drug companies that made price agreements with the Trump Administration under the Most Favored Nation (MFN) policy. These companies are AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. President Trump mentioned at a White House event that Americans have been paying the highest drug prices in the world, often subsidizing other countries. He said that starting that night, many common prescription drugs would be available at much lower prices through TrumpRx.gov. In 2023, most US patients had health insurance, but many still paid cash for their medicines. Notably, Eli Lilly and Novo Nordisk’s weight loss drugs, Zepbound and Wegovy, are included on TrumpRx. These drugs made over $21 billion in the US in 2025 alone. On TrumpRx, the price of injectable Wegovy drops from $1,349 to about $350, and the new Wegovy pill drops from $1,349 to $149 per month, depending on the dose. Novo also sells these drugs at similar low prices on its own website. Hims & Hers, an online health service, is selling a version of the Wegovy pill for as low as $49, making the pricing landscape more complex. Zepbound’s price on TrumpRx will drop from $1,088 to about $346, and as low as $299, depending on the dose. Lilly also sells Zepbound at low prices on its own website, LillyDirect. Pfizer is the biggest participant on TrumpRx, with over 30 medicines listed. Pfizer’s CEO, Albert Bourla, expressed pride in working with the administration to make medicines more affordable. Other drugs on TrumpRx include fertility treatments, inhalers, and insulin. More drugs from other companies that have made MFN deals will be added to TrumpRx in the coming months. In total, 16 major drug companies have made MFN deals with the Trump administration. MFN ties US drug prices to the lowest prices in other developed countries. Some companies have warned about financial challenges in 2026 due to these price changes. Pfizer, Eli Lilly, and Novo Nordisk expect lower sales for some of their products next year.